NCT00369564View on ClinicalTrials.gov

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Kidney CancerLeukemiaLymphomaNeurotoxicityPeripheral NeuropathySarcoma
Interventions
DRUG

glutamic acid

Given orally 3 times daily

OTHER

placebo

Given orally 3 times daily

Trial Locations (6)

33901

Lee Cancer Care of Lee Memorial Health System, Fort Myers

55404

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis

49503-2560

Butterworth Hospital at Spectrum Health, Grand Rapids

07601

Hackensack University Medical Center Cancer Center, Hackensack

28232-2861

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte

43205-2696

Nationwide Children's Hospital, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Children's Oncology Group

NETWORK

lead

University of South Florida

OTHER

NCT00369564 - Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer | Biotech Hunter | Biotech Hunter